Angiogenesis is essential for tumor growth and metastasis, and it plays a key role in the development and progression of lung cancer. Angiogenesis is determined by the tumor microenvironment and regulated by multiple signaling pathways. Lung cancer angiogenesis process can be summarized as follows: (1) Continuing growth of tumor promotes the so-called “angiogenic switch” in the microenvironment, starting the angiogenic process; (2) Matrix metalloproteinases (MMPs) induce the degradation and remodeling of extracellular matrix (ECM); (3) Endothelial cells migrate through the remodeled ECM as induced by platelet-derived growth factor (PDGF) and chemokines; (4) In presence of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), endothelial cells greatly proliferates; and (5) Lumen formation and vascular function are achieved by Dll4-Notch signaling. Currently, inhibition of angiogenesis has become an important option for lung cancer. Each stage of angiogenesis may become a potential target for treatment. New lights on the mechanisms of lung cancer angiogenesis is of great clinical significance for seaching effective anti-angiogenic and anti-lung cancer therapeutic methods.